MedTrace Logo

Tysabri Observational Program

NCT00493298 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6620

Last updated 2024-04-08

No results posted yet for this study

Summary

The primary objective of this study is to assess the long-term safety and impact on disease activity and progression of Tysabri in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Tysabri

According to the local prescribing information

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-29
Primary Completion
2023-11-01
Completion
2023-11-01

Countries

  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Mexico
  • Netherlands
  • Norway
  • Portugal
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493298 on ClinicalTrials.gov